News Headlines Article

More rules are needed to curb drug firms’ attempts to influence physicians
Washington Post

Nearly a decade ago when I was newly settled into private practice in Memphis, a drug representative for a new and powerful antibiotic stood in my office and asked whether I would like to attend a consultants’ meeting about the drug in Washington. He said I was a “thought leader” in the field and had been selected for his company’s speakers bureau. Flattered, I agreed, if my wife had no conflict with her on-call schedule.